Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 2, 1998, Pages 183-191

  Harder, Sebastian ^a   Baas, Horst ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 O METHYLDOPA; ANTIPARKINSON AGENT; BENSERAZIDE; BROMOCRIPTINE; DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DEGENERATIVE DISEASE; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MOTOR PERFORMANCE; NEUROLOGIC DISEASE; PARKINSON DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; ANTIPARKINSON AGENTS; BENSERAZIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOVEMENT DISORDERS; PARKINSON DISEASE;

EID: 0031715932     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90152-7     Document Type: Article

References (32)

1. Stocchi F, Nordera G, Marsden CD. Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Clin Neuropharm 1997;20:95-115.
2. Stern MB. Contemporary approaches to the pharmacotherapeutic management of Parkinson's disease. Neurology 1997;49(suppl):S2-9.
3. Cedarbaum JM. Clinical pharmacokinetics of anti-Parkinsonian drugs. Clin Pharmacokinet 1987;13:141-78.
4. Cedarbaum JM, Kutt H, McDowell FH. Clinical significance of the relationship between O-methyldopa levels and levodopa intake. Neurology 1988;38:533-6.
5. Leenders KL, Salmom EP, Turton DR, Tyrell P, Perani D, Brooks DJ, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteers and patients with Parkinson's disease. Arch Neurol 1990;30:24-30.
6. Poewe HW, Wenning GK. The natural history of Parkinson's disease. Neurology 1996;47(suppl 3):S146-52.
7. Sage JI, Mark MH. Basic mechanisms of motor fluctuations. Neurology 1994;44(suppl 6):S10-4.
8. Blanchet PJ, Allard P, Gregoire L, Tardif F, Bedard PJ. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci 1996; 23:189-93.
9. Harder S, Baas H, Rietbrock S. Concentration-effect relationship of levodopa in patients with Parkinson's disease. Clin Pharmacokinet 1995;29:243-56.
10. Nelson MV, Berchou RC, LeWitt PA, Kareti D, Galloway MP. Pharmacodynamic modeling of concentration-effect relationships after controlled release carbidopa/levodopa in Parkinson's disease. Neurology 1990;40:70-4.
11. Bredberg E, Tedroff J, Aquilonius SM, Paalzow L. Pharmacokinetics and effects of levodopa in advanced Parkinson's Disease. Eur J Clin Pharmacol 1990;39:385-9.
12. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A. Pharmacodynamic modeling of oral levodopa. Neurology 1993;43:367-71.
13. Cotzias GC, VanWoert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-9.
14. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
15. Hoehn MM, Yahr MD. Parkinsonism: onset progression and mortality. Neurology 1967;4:427-42.
16. Montgomery GK, Reynolds NC, Warren RM. Qualitative assessment of Parkinson's disease: study of reliability and data reduction with an abbreviated Columbia scale. Clin Neuropharmacol 1985;8:83-92.
17. Baas H, Stecker K, Fischer PA. Value and appropriate use of rating scales and apparative measurements in quantification of disability in Parkinson's disease. J Neurol Transm 1993;5:45-61.
18. Baruzzi A, Contin M, Albani F, Riva R. Simple and rapid micromethod for the determination of levodopa and 3-O-methyldopa in human plasma by HPLC with coulorimetric detection. J Chromatogr 1986;375:165-9.
19. Verotta D, Beal SL, Sheiner LB. Semiparametric approach to pharmacokinetic-pharmacodynamic data. Am J Physiol 1989;25:1005-10.
20. Elkoshi Z. Concentration/effect relationship following levodopa/carbidopa administration to "on-off" parkinsonian patients. Clin Neuropharmacol 1994;17:147-64.
21. Gasser T, Schwarz J, Arnold G, Trenkwalder C, Oertel WH. Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease. Arch Neurol 1992;49:1131-4.
22. Harder S, Baas H, Bergemann N, Demisch L, Rietbrock S. Concentration/effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation. Br J Clin Pharmacol 1995;39:39-44.
23. Baas H, Harder S, Bürcklin F, Demisch L, Fischer PA. Concentration/effect relationship of relationship of levodopa alone and under apomorphine in patients with Parkinson's disease. Clin Neuropharmacol 1998;21:86-91.
24. Harder S, Baas H. Influence of selegiline on the PK-PD relationship of levodopa in patients with Parkinson's disease [abstract]. Clin Pharmacol Ther 1998;63:198.
25. Gancher ST, Nutt JG, Woodward WR. Peripheral pharmacokinetics of levodopa in untreated, stable and fluctuating parkinsonian patients. Neurology 1987;37:940-4.
26. Triggs EJ, Charles BG, Contin M, Martinelli P, Cortelli P, Riva R, et al. Population pharmacokinetics and pharmacodynamics of oral levodopa in parkinsonian patients. Eur J Clin Pharmacol 1996;51:59-67.
27. Contin M, Riva R, Martinelli P, Albani F, Baruzzi A. Relationship between levodopa concentration, dyskinesias, and motor effect in parkinsonian patients: a 3-year follow-up study. Clin Neuropharmacol 1997;20:409-18.
28. Kempster PA, Frankel JP, Bovingdon M, Webster R, Lees AJ, Stern GM. Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. J Neurol Neurosurg Psychiatry 1989;52:718-23.
29. Ziv I, Zilkha-Falb R, Offen D, Shirvan A, Barzilai A, Melamed E. Levodopa induces apoptosis in cultured neuronal cells: a possible accelerator of nigrostriatal degeneration in Parkinson's disease? Mov Disord 1997;12:17-23.
30. Rajput AH, Fenton ME, Birdi S, Macaulay R. Is levodopa toxic to human substantia nigra? Mov Disord 1997; 12:634-8.
31. Gervas J, Muradas B, Bazan E, Aguado E, deYebenes J. Effects of 3-OM dopa on monoamine metabolism in rat brain. Neurology 1983;33:278-82.
32. Nutt JG, Woodward WR, Gancher ST, Merrick D. 3-O-Methyldopa and the response to levodopa in Parkinson's disease. Ann Neurol 1987;21:584-8.